HK Stock Market Move | LONGCHEER (09611) rose by more than 8% recently, acquiring 60% of the shares of Ke Jicheng and Jia Metal to accelerate the expansion of top customer resources in North America.
Longqi Technology (09611) rose more than 8%, as of the time of writing, it has risen by 7.7%, to 22.36 Hong Kong dollars, with a turnover of 55.84 million Hong Kong dollars.
LONGCHEER (09611) rose more than 8%, as of the time of writing, it rose 7.7% to HK$22.36, with a turnover of HK$55.834 million.
On the news front, recently, LONGCHEER announced the "Announcement on the Acquisition of 60% Equity of Kejuecheng Precision Technology (Dongguan) Co., Ltd. and Dongguan Jiya Metal Products Co., Ltd. and the Signing of Related Equity Transfer Agreements". The announcement stated that LONGCHEER will acquire a total of RMB 540 million for a 60% stake in Kejuecheng and Jiya Metal respectively. After the completion of this transaction, Kejuecheng and Jiya Metal will become controlled subsidiaries of LONGCHEER and will be included in the consolidated financial statements. Huaxin Securities believes that this move is aimed at strengthening the company's technological capabilities in precision manufacturing areas such as AI terminal heat dissipation technology, and accelerating the expansion of its top North American customer resources.
Huaxin Securities pointed out that the company has already achieved the design and mass production of Intel, AMD, and Qualcomm platform products, with product forms covering thin and light high-performance laptops, Mini PCs, handheld consoles, etc. The company has successfully obtained mass production orders from several international top customers and entered their global supply chain system. With the reconstruction of AI Agent on the edge side, the company is leveraging its full-chain capabilities to promote AI PCs as the core carrier integrating local computing power with cloud ecosystem.
Related Articles

SBP Group (01177) spent 10.0473 million Hong Kong dollars to repurchase 1.81 million shares on April 27th.

UNI MEDICAL (02666) subsidiary completes the issuance of 500 million yuan medium-term notes.

AstraZeneca PLC Sponsored ADR (AZN.US) "dual immunotherapy" new indication approved for market in China
SBP Group (01177) spent 10.0473 million Hong Kong dollars to repurchase 1.81 million shares on April 27th.

UNI MEDICAL (02666) subsidiary completes the issuance of 500 million yuan medium-term notes.

AstraZeneca PLC Sponsored ADR (AZN.US) "dual immunotherapy" new indication approved for market in China






